Showing results (1-10 of 22) with videos related to
Sort By:
Pageof 3
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Gene expression profiling as a prognostic tool in multiple myelomaHarmony Black, Siobhan GlaveyCancers|May 13, 2023
Adoptive Immunotherapy and High-Risk MyelomaCatherine Duane, Michael O'Dwyer, Siobhan GlaveyCancers|March 29, 2023
Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve SafetyDawn Swan, Philip Murphy, Siobhan Glavey, et al.International Journal of Molecular Sciences|July 29, 2023
Genetic Abnormalities in Extramedullary Multiple MyelomaRoisin McAvera, John Quinn, Philip Murphy, et al.Haematologica|March 6, 2025
Significant risk of venous thromboembolism associated with targeted anti-myeloma immunomodulatory drugs. Comment on: Targeted anti-cancer agents and risk of venous thromboembolismCatherine Duane, Siobhan Glavey, John Quinn, et al.Journal of Thrombosis and Haemostasis : JTH|June 1, 2022
The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignanciesClaire Comerford, Siobhan Glavey, John Quinn, et al.Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Potential mechanisms of resistance to current anti-thrombotic strategies in Multiple MyelomaClaire Comerford, Siobhan Glavey, Jamie M O'Sullivan, et al.Microrna (Shariqah, United Arab Emirates)|July 30, 2014
The role of miRNAs in plasma cell dyscrasiasSiobhan Glavey, Salomon Manier, Antonio Sacco, et al.Biochimica Et Biophysica Acta|April 9, 2014
Role of endothelial progenitor cells in cancer progressionMichele Moschetta, Yuji Mishima, Ilyas Sahin, et al.Immunological Reviews|December 17, 2014
Targeting the bone marrow microenvironment in multiple myelomaYawara Kawano, Michele Moschetta, Salomon Manier, et al.Pageof 3